Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group

OBJECTIVE: The standard treatment for chronic myeloid leukemia (CML) is the continuous use of tyrosine kinase inhibitors (TKIs), which results in a favorable prognosis for the majority of patients. Recent studies have identified cardiovascular diseases (CVDs) as late adverse events (AEs) related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiwata, Masahiko, Itonaga, Hidehiro, Sato, Shinya, Hashimoto, Miki, Fujioka, Machiko, Kasai, Sachie, Sakamoto, Hikaru, Toriyama, Eo, Nakashima, Jun, Kamijo, Rena, Kitanosono, Hideaki, Kobayashi, Yuji, Horai, Makiko, Taguchi, Masataka, Matsuo, Masatoshi, Makiyama, Junya, Takasaki, Yumi, Matsuo, Emi, Horio, Kensuke, Ando, Koji, Sawayama, Yasushi, Taguchi, Jun, Kawaguchi, Yasuhisa, Tsushima, Hideki, Imanishi, Daisuke, Imaizumi, Yoshitaka, Yoshida, Shinichiro, Jo, Tatsuro, Nonaka, Hiroaki, Moriuchi, Yukiyoshi, Nagai, Kazuhiro, Yokota, Ken-ichi, Hata, Tomoko, Miyazaki, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355380/
https://www.ncbi.nlm.nih.gov/pubmed/33612681
http://dx.doi.org/10.2169/internalmedicine.6620-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355380/
https://www.ncbi.nlm.nih.gov/pubmed/33612681
http://dx.doi.org/10.2169/internalmedicine.6620-20

Ejemplares similares